Jeffrey Albers
Chairman at BLUEPRINT MEDICINES CORPORATION
Net worth: 17 M $ as of 2024-03-30
Profile
Currently, Jeffrey W. Albers holds the position of President, Chief Executive Officer & Director at Blueprint Medicines Corp. Mr. Albers is also on the board of Magenta Therapeutics, Inc. and Kymera Therapeutics, Inc. and Director-New England Division at American Cancer Society, Inc. He previously occupied the position of Vice President-US Hematology & Oncology Business at Sanofi and VP-US Hematology & Oncology Business Unit at Genzyme Corp. (a subsidiary of Sanofi), Attorney at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC and President at Algeta ASA. Mr. Albers received an undergraduate degree from Indiana University and a graduate degree and an MBA from Georgetown University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-19 | 176,050 ( 0.29% ) | 17 M $ | 2024-03-30 | |
| 2023-03-30 | 260 ( 0.00% ) | 7 800 $ | 2024-03-30 | |
| 2024-02-20 | 0 ( -.--% ) | - $ | 2024-03-30 | |
SPYRE THERAPEUTICS, INC
-.--% | 2023-11-21 | 0 ( -.--% ) | - $ | 2024-03-30 |
Jeffrey Albers active positions
| Companies | Position | Start |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chairman | - |
| KYMERA THERAPEUTICS, INC. | Director/Board Member | 2020-06-30 |
| SPYRE THERAPEUTICS, INC. | Director/Board Member | 2023-11-26 |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Corporate Officer/Principal | - |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | - |
MOMA Therapeutics, Inc.
 MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Chairman | 2023-02-07 |
Pheon Therapeutics Ltd.
 Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Chairman | - |
Former positions of Jeffrey Albers
| Companies | Position | End |
|---|---|---|
| MAGENTA THERAPEUTICS | Director/Board Member | 2023-09-11 |
| ALGETA ASA | President | 2014-04-29 |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░ ░░░░░ ░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Jeffrey Albers
| Indiana University | Undergraduate Degree |
| Georgetown University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| SANOFI | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Private companies | 8 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC provides legal services. The firm offers services to the communications, education, environmental, health, immigration, public finance, real estate and tax industries. The company was founded in 1933 and is headquartered in Boston, MA. | Commercial Services |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
American Cancer Society, Inc.
American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Commercial Services |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
MOMA Therapeutics, Inc.
MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Health Technology |
Pheon Therapeutics Ltd.
Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Albers
